Regeneron Pharmaceuticals (NASDAQ:REGN) said the European Medicines Agency’s Committee for Medicinal Products for Human Use ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human ...

Regeneron on Friday said the recommendation covers adults with adults with relapsed and refractory multiple myeloma who have received at least three prior therapies, including a proteasome inhibitor, ...

Pharmaceuticals announced that the European Medicines Agency’s, EMA, Committee for Medicinal Products for Human Use, CHMP, has ...

MILWAUKEE, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Brady Corporation (NYSE:BRC) ("Brady” or "Company”) announced that Anne De Greef-Safft has joined its Board of Directors, effective February 25, 2025.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion ...

Lenacapavir is a twice-yearly injectable medication designed to be used as pre-exposure prophylaxis (PrEP). The FDA is giving ...

Regeneron Pharmaceuticals' fourth quarter results beat my and Wall Street analysts' expectations. See why REGN stock is a top ...

The FDA accepted Regeneron’s BLA resubmission for linvoseltamab in relapsed or refractory multiple myeloma, with a decision expected by July 10, 2025.

AbbVie got FDA approval for antibiotic treatment Emblaveo. Regeneron’s Linvoseltamab BLA was accepted for FDA review for the treatment of relapsed/refractory multiple myeloma. FDA has approved an ...

A systematic diagnostic approach should be used to differentiate AAV from multiple myeloma. An elderly patient who was initially suspected of having antineutrophil cytoplasmic antibody ...